Anemia: Causes, symptoms and treatment – Livescience.com

Anemia also known as iron-poor blood is a condition that develops when either the blood doesn't have enough red blood cells or the concentration of hemoglobin in red blood cells is very low. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen from the lungs to the rest of the body. When there are fewer red blood cells than normal or low levels of hemoglobin, the body doesn't get enough oxygen-rich blood for healthy functioning, which is what causes the symptoms of anemia.

Anemia is the most common blood disorder in the United States, affecting nearly 3 million Americans, according to the Centers for Disease Control and Prevention (CDC).

The term anemia is a broad one that represents several hundred different conditions some of them mild and treatable, others that are quite serious, said Dr. Nancy Berliner, chief of hematology at Brigham and Women's Hospital in Boston. There are three reasons that people are anemic, Berliner said: Either their body can't make enough red blood cells, something is destroying the red blood cells faster than their body can make news ones or blood loss (from menstrual periods, colon polyps or a stomach ulcer, for example) is greater than blood cell production.

There are more than 400 different types of anemia, according to the Pacific Heart, Lung & Blood Institute. Here are a few of the more common and better understood types:

Iron-deficiency anemia: The most common form of anemia is caused by low-iron levels in the body. Humans need iron to make hemoglobin, and most of that iron comes from dietary sources. Iron-deficiency anemia can result from a poor diet or from blood loss through menstruation, surgery or internal bleeding.

Pregnancy also increases the body's need for iron because more blood is needed to supply oxygen to the developing fetus, which may quickly drain the body's available iron stores, leading to a deficit. Problems absorbing iron from food because of Crohn's disease or celiac disease can also result in anemia.

Vitamin deficiency anemia: Besides iron, the body also needs two different B-vitamins folate and B12 to make enough red blood cells. Not consuming enough B12 or folate in the diet or an inability to absorb enough of these vitamins can lead to deficient red blood cell production.

Sickle cell anemia or sickle cell disease (SDC): This inherited disease causes red blood cells to become crescent-shaped rather than round. Abnormally shaped red cells can break apart easily and clog small blood vessels, resulting in a shortage of red blood cells and episodes of pain, according to the Mayo Clinic. People become chronically anemic because the sickle-shaped red cells are not pliable and can't get through blood vessels to deliver oxygen, Berliner said.

SDC occurs most often in people from parts of the world where malaria is or was common, according to the CDC; the sickle cell trait may provide protection against severe forms of malaria. In the U.S., SDC affects an estimated 100,000 Americans.

Thalassemia: Thalassemia is an inherited blood disorder that results in lower-than-normal levels of hemoglobin. This type of anemia is caused by genetic mutations in one or more of the genes that control the production of hemoglobin, according to the National Heart, Lung & Blood Institute (NHLBI).

Aplastic anemia: Aplastic anemia is a rare, life-threatening condition that develops when bone marrow stops making enough new blood cells, including red cells, white cells and platelets.

Aplastic anemia may be caused by radiation and chemotherapy treatments, which can damage stem cells in bone marrow that produce blood cells. Some medications, exposure to toxic chemicals like pesticides, viral infections and autoimmune disorders can also affect bone marrow and slow blood cell production.

Hemolytic anemias: This disorder causes red blood cells to be destroyed faster than bone marrow can replace them. Hemolytic anemias may be caused by infections, leaky heart valves, autoimmune disorders or inherited abnormalities in red blood cells, according to the American Society of Hematology.

Anemia of inflammation: Also called anemia of chronic disease, anemia of inflammation commonly occurs in people with chronic conditions that cause inflammation. This includes people with infections, rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, HIV/AIDS and certain cancers, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

When a person has a disease or infection that causes inflammation, the immune system responds in a way that changes how the body works, resulting in anemia. For example, inflammation suppresses the availability of iron, so the body may not use and store the mineral normally for healthy red blood cell production, Berliner said. Inflammation may also stop the kidneys from producing a hormone that promotes red blood cell production.

The risk for anemia is higher in people with a poor diet, intestinal disorders, chronic diseases and infections. Women who are menstruating or pregnant are also prone to the disorder.

The risk of anemia increases with age, and about 10% to 12% of people over 65 are anemic, Berliner said. But the condition is not a normal part of aging, so the cause should be investigated when it's diagnosed, she said. Older adults may develop anemia from chronic diseases, such as cancer, or iron-deficiency anemia from abnormal bleeding.

According to NHLBI, the following types of people have an increased risk of developing anemia:

Mild forms of anemia may not cause any symptoms. When signs and symptoms of anemia do occur, they may include the following, according to the NHLBI:

The first test used to diagnose anemia is a complete blood count, which measures different parts and features of the blood: It shows the number and average size of red blood cells, as well as the amount of hemoglobin. A lower-than-normal red blood cell count or low levels of hemoglobin indicate anemia is present.

If more testing is needed to determine the type of anemia, a blood sample can be examined under a microscope to check for abnormalities in the size and shape of the red cells, white cells and platelets.

Related: This man's taste buds disappeared because of a blood condition

The treatment of anemia depends on the specific type of anemia, Berliner said, and anemias caused by nutritional deficiencies respond well to changes in diet. People with iron-deficiency anemia may need to take supplemental iron for several months or longer to replenish blood levels of the mineral. Some people, especially pregnant women, may find it hard to take iron because it causes side effects, such as an upset stomach or constipation, Berliner said.

For vitamin-deficiency anemias, treatment with B12 or folate from supplements (or a B12 shot) and foods, can improve levels of these nutrients in the blood, Berliner said.

Serious problems, such as aplastic anemia, which involves bone marrow failure, may be treated with medications and blood transfusions. Severe forms of thalassemia might need frequent blood transfusions.

Treatment for sickle cell anemia may include pain medications, blood transfusions or a bone marrow transplant.

Additional resources:

This article is for informational purposes only, and is not meant to offer medical advice.

Read this article:
Anemia: Causes, symptoms and treatment - Livescience.com

Here’s Why CRISPR Stocks Fell in January – The Motley Fool

Spurred by promising clinical results in an important trial, each of the three major CRISPR stocks had a great performance in the second half of 2019. Unfortunately, they didn't keep the momentum going in the first month of 2020.

Shares of Intellia Therapeutics (NASDAQ:NTLA) fell 18.8% in January, according to data provided by S&P Global Market Intelligence. That was followed by a 14.7% loss for shares of CRISPR Therapeutics (NASDAQ:CRSP) and a 10.7% tumble for shares of Editas Medicine (NASDAQ:EDIT).

While each has recovered some ground in the first week of February, this trio of pharma stocks is no stranger to volatility. Investors should probably expect that to continue as clinical programs advance in 2020.

Image source: Getty Images.

In November, CRISPR Therapeutics reported data for the first two individuals in the trial, one with sickle cell disease (SCD) and one with transfusion-dependent beta thalassemia (TDT), treated with its lead drug candidate CTX001. Both enjoyed significant benefits in their standard of living, which investors interpreted as a sign that CRISPR gene editing might actually live up to the hype.

That fueled annual gains of 113% for CRISPR Therapeutics last year. While Editas Medicine and Intellia Therapeutics gained only 30% and 7%, respectively, each had been sitting at a year-to-date loss in October.

What relevance does that have for the tumbles taken in January? First, it's not unusual for stocks to regress to the mean. Stocks that are red hot eventually cool off, while those that tumble without good reason eventually recover some ground.

Second, and the more important consideration for investors, is that the early stage results for CTX001 mean relatively little for the industry's pipeline of CRISPR-based gene editing drug candidates.

Consider that CTX001 is an ex vivo tool. Researchers harvest bone marrow from patients, extract specific types of stem cells, and engineer those with CTX001. The engineered stem cells are then grown in the lab before being reinjected into the patient.

Many other CRISPR-based drug candidates are designed as in vivo tools. That means the gene editing payloads are designed to engineer a patient's DNA while inside the body. An in vivo approach is inherently more complex and will be more difficult to control compared to an ex vivo approach.

Put another way, investors cannot take the promising, early stage results from CTX001 and extrapolate it broadly across all first-generation CRISPR tools. Wall Street certainly isn't, if the correlation between technical approach and stock performance is any guide.

Consider that the two most advanced drug candidates from CRISPR Therapeutics rely on ex vivo engineering. By contrast, the lead drug candidate from Editas Medicine relies on in vivo methods.

The lead pipeline asset from Intellia Therapeutics is also an in vivo tool, though unlike the lead assets from its peers, it has yet to advance to clinical trials.

Investors should expect 2020 to be a busy year for these CRISPR stocks. CRISPR Therapeutics will have more clinical data from CTX001 and the first set of data for its lead oncology asset CTX110.

Similarly, Editas Medicine should have results for EDIT101 and progress additional assets, while Intellia Therapeutics is preparing to finally enter the clinic with NTLA-2001 in the second half of the year.

Investors cannot know if the next batch of results will be as rosy as the initial data for CTX001, but they can probably expect another year of volatile stock movements.

See the article here:
Here's Why CRISPR Stocks Fell in January - The Motley Fool

Victoria Beckham says this product is the best product you will ever use – Marie Claire UK

Victoria Beckham is yet again busting out the big guns this time with hernew Cell Rejuvenating Power Serum.

Having combined forces with renowned stem cell researcher Augustinus Bader for a second time, the Cell Rejuvenating Power Serumsecures Beckhams position as the one to watch in the world of game-changing beauty.

Yesterday she took to instagram to declare, the science behind this is so incredible and I really notice a difference in my pore size and the fine lines around my eyes.

As if further proof were needed, Beckham posted a gorgeous video of her make-up free, luminous skin.

And shed be right. This serum is grounded in credible stem cell research by an unassuming scientist whos never attended a fashion show. In fact, Bader has spent the last 30 years at a medical clinic in Leipzig, Germany, treating burns victims.

Last November, Victoria Beckham Beauty launched its first skincare product, Cell Rejuvenating Priming Moisturiser, together with Bader. It incorporated his patented TFC8 technology. After using it, we now strongly believe that you need amino acids, vitamins and molecules that activate lazy stem cells to defend and repair the skin.

Youll find an even heftier dose of TFC8 in the Power Serum. It also reduces redness with niacinamide; protects againstpollution with antioxidant vitamin E and hydrates and strengthens with skin-quenching hyaluronic acid.

All the know-how is based upon scientific knowledge of what our skin cells really need to work at their best, says Bader.

Of course, this wouldnt be a Victoria Beckham Beauty product if the packaging didnt scream chic, too. Think frosted glass, simple black typography and a pipette to dispense just the right amount of serum every time.

But as well as looking good, the bottle does good, too. It is made of recyclable glass and can be disassembled so each piece enters the proper recycling stream.

If that wasnt enough to get your eco juices flowing, it is packaged in a 100% post-consumer waste carton and shipped in protective, biodegradable foam that can be dissolved under running water or disposed in compost. Pretty cool, no?

Made to be used before thePriming Moisturiser (or any other moisturiser youre using), you can also use the Cell Rejuvenating Power Serum in conjunction with Augustinus Baders cult The Cream or Rich Cream. Simply apply it first if you feel your skin needs extra cosseting.

Something tells us the Cell Rejuvenating Power Serum is yet another product Victoria Beckhams fans will instantly adore.

P.S. You had us at the selfie, VB.

View original post here:
Victoria Beckham says this product is the best product you will ever use - Marie Claire UK

How the next trip to the moon will get us ready for Mars – Deseret News

The following is a transcript from a recent interview conducted on KSL Newsradios Inside Sources, hosted by Deseret News opinion editor Boyd Matheson.

Boyd Matheson: Were very pleased today to be joined by the NASA Administrator Jim Bridenstine. Jim was nominated by President Donald Trump, confirmed by the Senate and sworn in as NASAs 13th administrator in April of 2018. Administrator Bridenstine was also previously elected to the United States Congress as a representative from Oklahomas 1st District, began his career in the U.S. Navy flying E2C Hawkeyes off the USS Abraham Lincoln aircraft carrier and has a host of other experience. Administrator Bridenstine, thanks so much for joining us today.

Jim Bridenstine: Its my honor. Thanks for having me.

BM: But we got to know each other a little bit back when you were in Congress. Im sure youre not missing those days today as opposed to being able to to play with all of the wonderful assets at NASA.

JB: Yeah, Ill tell you, it looks like the Hill is a really rough place to be right now. So Im very happy that Im at NASA.

Boyd Matheson: Well, its a great spot. Its a great spot for you. Many people have asked the question, you know, has NASA lost that ability to capture the imaginations of the American people? And I cant think of anyone better prepared to lead that effort than you.

JB: Well, I appreciate you saying that. I will tell you, there have been some pretty dark days at NASA going back about a decade. We had a moment there, where we retired the space shuttles. And then we canceled the replacement to the space shuttle, the Constellation program. And there was just a lot of a lot of concern about, What is the agency going to do? But were bringing it back and weve got some really big programs that are very close to completion now. And I will tell you with the president and the vice president giving us bigger budgets and bigger missions, with bipartisan support in the House and the Senate. I think our future is very bright and all of America will be very proud.

BM: Thats exciting to hear. And I and I want to dive into some of those programs and some of those initiatives moving forward and and maybe start with the Artemis program. I think thats probably one that should capture captured the nations attention. Tell us about that.

JB: Yeah, so we have a big agenda to go back to the moon. I like to say were going to go forward to the moon. I say forward because were going in a way thats never been done before. This time when we go to the moon, were going sustainably. In other words, were going to stay at the moon. Were going to learn how to live and work on another world for long periods of time. And were going to use the resources of the moon in order to live namely the water ice. When we think about the water ice, water ice represents water to drink, of course. It also represents air to breathe. And hydrogen and oxygen thats rocket fuel. Hydrogen and oxygen is the same rocket fuel that powered the space shuttles. And its available all over the south pole of the moon, were talking about hundreds of millions of tons of water ice on the south pole of the moon.

And of course, that was just discovered in 2009. So really, you know, 10 years ago, 11 years ago, this major discovery was made. And that should have instantaneously changed our space program. We should have immediately said, OK, were going to go back to the moon, were going to learn how to use the resources of the moon in order to live and work for long periods of time, and were going to take that knowledge. Were going to take that knowledge to Mars, and thats really what the Artemis program is all about. Its about a sustainable return to the moon. And then were going to take that knowledge and go to Mars. The thing its also important to remember is Artemis, in Greek mythology, is the twin sister of Apollo. And we loved the Apollo program. But remember, in the Apollo days, all of our astronauts came from fighter pilot backgrounds and test pilot backgrounds. And in those days, there were no opportunities for women.

Well, now we have this very diverse, highly qualified astronaut corps that includes women, and were going to go to the moon sustainably, with this very diverse astronaut corps under the name of Apollos twin sister, her name is Artemis. And she was in fact, the goddess of the moon. So I think its really an amazing story to share. You know, America has changed and the space program has changed. And I think its a good story that America can be proud of.

BM: Yeah, that is one that I think the American people can get behind, especially in a year like this where were celebrating womens suffrage and a host of other firsts and a lot of great advancements there as well.

So as you look at that Artemis program, you mentioned that it would be really the place where you would be sustainable and then be able to use that to parlay our way to Mars. Tell us a little bit more about that.

JB: So what we need to do is we need to learn how to live and work on another world for long periods of time. The challenge with Mars is that Mars and Earth are on the same side of the sun once every 26 months. So when you go to Mars, you have to be willing to stay for a couple of years. Were not talking about a couple of days, you have to go for a couple of years. Which means we have to use the resources of Mars to live and work for long periods of time. Well, the glory of the moon is that its always a three-day journey home. And so we can go to the moon, we can learn how to live and work on another world. We can prove the capabilities, build the technologies, utilize the water ice, as well as the regoliths and other minerals there on the on the surface of the moon. And then we know that if something goes wrong, we can always make it home. Which, of course, we proved that on Apollo 13, for example. Something went terribly wrong on the way to the moon, and our brave astronauts were able to make it home. Thats why the moon is so valuable. If we were to learn everything for the first time on Mars, the probability of success would go down, and so the moon really represents the best course for us to learn what is necessary to go to Mars. So, around the moon, were going to have in orbit what we call the (Lunar) Gateway.

The Gateway is a space station in orbit around the moon, and were already under contract to build the first elements of the Gateway, and that Gateway in orbit around the moon is going to give us access to the surface of the moon. Its maneuverable, it has solar electric propulsion, so it can make sure we can get to all parts of the moon. We learned in 2009, that theres hundreds of millions of tons of water ice on the south pole of the moon. Whats interesting is how come we didnt know that from 1969 all the way up until 2009? For 40 years, we missed the fact that there was water ice in hundreds of millions of tons, probably a lot more, on the south pole of the moon. Well, we missed it because we landed at the equatorial region six times with humans. We had 12 humans that landed on the moon six times, but they were all in the equatorial regions where there is no water ice. Well, what the Gateway enables us to do is because its maneuverable, it can go it can go to all the different orbits around the moon. And it can get us access to the north pole and the south pole. And we can go to where the resources are, and we can learn how to use those resources.

Well, that same Gateway is also evolvable. So it can be evolved to be the deep space transport that takes our first astronauts to Mars, for example. So it gives us capability and flexibility. At first, its going to be all about getting us access to the moon and being a command module for moon activities. But eventually, its going to take us all the way to Mars.

BM: Thats fantastic. I want to shift gears a little bit now and talk about some of the interesting components to me in terms of how we continue to sustain this. Obviously, theres private groups that are out there. So you know, some are questioning whats the role of the federal government now public-private partnerships there as well as the international connection. Obviously, were weve been reliant on our international allies and alliances as it relates to space for the last number of years. Give me a sense both in terms of continued role for NASA, from the federal government and the private sector, as well as our international component.

JB: Yeah, great question. So its another way that this time when we go to the moon, its entirely different than weve ever done before. We do have a very robust commercial marketplace. You know, people who listen to this maybe on the internet or however they listen to it, maybe they they have their internet from internet broadband from space, or maybe people have DirecTV or Dish Network or XM Radio. Theres all these space based communication capabilities that are transformational and remote-sensing capabilities that are transformational, but heres the point: The point is there is a very healthy and robust commercial marketplace for activities in space.

And so NASA has made a decision that instead of us purchasing, owning and operating all of the hardware to get things to space, what if we buy the services from this very robust commercial marketplace. So it goes from NASA. Were going from NASA purchasing, owning and operating the hardware to NASA becoming a customer, one customer of many customers. And when we do that, weve been doing it, for example, to resupply the International Space Station.

When we resupply the International Space Station, we buy a service, we dont purchase, own and operate our own rockets. And it has been very successful. Weve been very successful at driving down costs, which of course increases access. And were doing that now, in fact this year this is a big deal. This year were going to launch American astronauts on American rockets from American soil. And were doing it with a program that we call Commercial Crew. So where we are going to launch on in this case, weve got two providers. One is SpaceX with the Dragon Crew capsule, and the other is Boeing, with whats called the Starliner Crew capsule. And were buying services from these two countries to get our astronauts back and forth to the International Space Station.

The idea being that we want to be one customer of many customers. Were hoping that there is a very robust commercial marketplace that includes humans flying into space. And theres a lot of reasons to have humans in space. I can get into those in a few minutes. But when we think about commercial resupply of the International Space Station, commercial crew to the International Space Station, and now were going to start building commercial space stations, that will eventually be the replacements for the International Space Station. So theres a robust commercial marketplace where NASA can be a customer. And we can be one of many customers. And we can have numerous providers that are competing against each other on cost and innovation. The goal being that we need to drive down costs.

So were doing that already in low Earth orbit. Now what we need to do is we need to take that model all the way to the moon. So when we buy the lander that takes our astronauts to the surface of the moon, that lander is going to be a commercial lander, and we want to buy the service. Now make no mistake, were going to invest a lot in developing that capability. So it is a public-private partnership. But we want to have numerous providers that are competing against each other, driving down costs. But we want to do it as a service. And then again, we can be one customer of many with numerous providers that are driving down costs.

BM: Thats excellent. So I want to drill down. You mentioned getting more humans into space. And I want to attack that kind of in two tiers. One obviously, is just the regular consumer, the individuals out there, but then also as it relates to Space Force, and what that means from a military perspective as well.

JB: Yeah, so when we think about technologies that were proving right now on the International Space Station, we are proving that on the International Space Station, for example, we can we can compound pharmaceuticals in orbit around the Earth in a way that cannot be done in the gravity well of Earth. Were proving that we can create immunizations that cannot be created in the gravity well of Earth. We are proving that we can in fact, print in 3D human organs on the International Space Station using adult stem cells. So when we use adult stem cells to print human organs in 3D, what that means is that its going to have all of these technologies have amazing breakthrough capabilities for human life here on earth.

And that, of course, the goal being that will drive investment, private capital into the market to do more activities in space than ever before. So were using the International Space Station right now to create those markets.

But also, we think about people who have macular degeneration and they lose their eyesight. Were proving that we can create artificial retinas for the human eyeball in space in a way that you cannot create them on earth so that people who have macular degeneration dont have to lose their eyesight. And theres advanced materials like fiber-optic networks that can be created so pristinely in space that you dont have to have repeaters and of course, that drives down the cost of laying fiber-optic cables throughout, you know, cities. So theres advanced manufacturing, theres industrialized biomedicine. Theres all of these different capabilities that are being developed that can only be done in a zero gravity environment, they cannot be done on earth. And once these capabilities are proven, the goal would be that we would see lots of investment in space.

Now to your question about the Space Force. Remember why we have a navy. We have a Navy because there is commerce on the high seas, and without a navy, that commerce is vulnerable. And thats precisely why the United States of America is powerful, because we have an amazing economy with amazing free market enterprise. And then we also have the strength to back it up. The challenge with space is, as you can imagine, were already seeing, you know, its already a $400 billion market for commercial activities in space and its soon becoming a trillion dollar market. And there are nations out there like China, who have called space the American Achilles heel. Because of how dependent we are on space.

We think about the GPS constellation for navigation. It also is used for regulating flows of electricity on the power grid and regulating flows of data on wireless networks like the cellphone Im speaking on right now. Its also used for every banking transaction, a GPS timing signal is necessary. Without GPS, there is no banking. So we are dependent on space in a way that most Americans do not understand. And we want to grow this economy in space. And remember, the economy is on Earth, the activities are in space. But we want to grow it and in order to grow it countries around the world who believe they can bring America to its knees by destroying space, they need to understand that we are not going to let anybody get an advantage over the United States by threatening space.

NASA does not do Space Force. We are not a defense organization. NASA is a science and discovery organization. But Ill tell you, we are developing an economy and that economy is is put in jeopardy if we dont have security in space. And thats what the Space Force is all about.

BM: Thats fantastic. Just in our final few minutes here, Administrator Bridenstine. I just wanted you to talk to the American people in in general, you know. Theyve been listening to this for the last few minutes. What is it that you hope every American thinks about, what do you hope we do about our relationship to space and enter the future of the space program?

JB: Yeah, so I think the future of the space program is very bright. Were seeing bipartisan support in the House and in the Senate. Weve got strong support from the president. The president has put the vice president in charge of the National Space Council, of which I am a member. And so the amount of support were having right now, I dont think we have had this much support since the 1960s, when we had people on the moon, you know, in the early days, and of course, the early 1970s, as well.

So I think the space program is strong. I think its important for people to recognize how we are dependent on space in ways that most people dont know. And thats why its important for the American economy. Its important for national security. And these are the activities that we need to continue to grow. And of course, NASA plays strong. You mentioned international partners. Were growing our international partners.

Ill tell you, when we canceled the Constellation program and retired the space shuttles, a lot of our international partners were running for the hills because they thought America didnt have a vision. Well, now were bringing them all back. They all want to be with us on going to the moon. Theyve never been to the moon. Remember when we went to the moon last time it was America alone. This time when we go to the moon, were leading a coalition of nations. It puts the United States of America in the drivers seat to be the leader. But it also gives us access to more resources and capabilities.

And so this is an important program for the nation, for diplomacy, for economics, for national security. And I think its a point of pride and prestige for our nation. And so I would just encourage Americans out there who are listening, to know that your country is doing what it can to make sure that America leads and thats what were doing. Were leading.

BM: Fantastic. NASA Administrator Jim Bridenstine. Thank you so much for joining us. I appreciate your leadership of NASA and our space program and there are some very exciting things ahead that really will capture the imagination of the nation. Thanks so much for being with us today.

JB: Thank you, always. Will do it again.

Originally posted here:
How the next trip to the moon will get us ready for Mars - Deseret News

Biological robots, that is a thing now – 702

There are two stories I would like to tell with this edition of Business Unusual, the first is about the Darpa funded research to build robots out of living cells, the second is the incredible history of the animal that was used to build the first biological robots - Platannas.

The Defense Advanced Research Projects Agency (DARPA) is an agency of the American Department of Defense. It has funded many projects for military projects that in time have come to be used for civilian applications. The best-known example is the predecessor of the internet.

Why a military agency would fund research into creating living robots might be concerning but the stated objectives include managing environmental clean-ups or improving drug delivery which certainly are worthy pursuits. Of greater concern, are the ethical questions that are raised by creating new forms of a living organism. At the moment the designs dont attempt to make them self-replicating but that is part of the future plans.

Robots typically are designed and programmed to perform a specific task. Until now they would have been constructed out of non-living materials. These robots are also designed for a specific task but created from living cells. The choice of cell and the specific construction determines what action or function the living robot can perform.

One function that was attempted was movement. Starting from scratch researchers used stem cells from a frog to create skin cells and heart cells. The heart cells are muscles and so can contract while heart cells are able to do so rhythmically. Using those properties a machine learning program was tasked with testing thousands of configurations to determine which design would use the least cells to achieve the motion required. Once the best designs were determined, the living robots were constructed by researchers manipulating individual cells under a microscope.

The tiny constructed robots demonstrated that living robots designed by computer could offer an alternative to traditionally constructed machines. Future versions would look to make the constructions more complex and eventually able to self replicate.

One intended function was using a swarm of living robots with the ability to decompose plastic to be used to remove microplastics in the ocean. That may be a long way off, but if it is to become a reality the best time to start working on it is now.

Another application might be to not find plastic in the sea, but cancers in your body. Your body is already very good at doing so, but as we age and at certain times of our lives it becomes more challenging to correctly identify and kill cancer cells when they are still only tiny tumours.

This would require building robots consisting of your own body cells arranged in a way to allow them to move through the body and specifically find the corrupted cells. Adding them in numbers as we age may reduce the chance of developing tumours or even help the body recover after exposure to damaging external factors like sun damage to your skin.

This too is a long way off, but if successful and added to the many other options for extending and improving our lives then the research is most welcome.

_Image credit: Wikipedia African clawed frog_

Setting the other issues relating to building living robots aside, you might wonder why a frog from South Africa was chosen to build the first living robots.

It was not a random choice but points to a fascinating history that makes this particular frog one that has helped humanity overcome medical issues on a number of occasions.

A pregnancy test these days simply requires peeing on a stick. The reaction to a specific hormone in the urine can be isolated in minutes and let you know if you are pregnant within days of it occurring. It was not always this easy, the first method we are aware of would see a potentially pregnant woman urinate on ungerminated wheat and barley and wait a week or so to see if it germinated. Incredibly it works and was first mentioned over 3 000 years ago by the Egyptians. It was scientifically tested in the 1960s and found to be 70% accurate.

There were a variety of other methods used most on the expectation that something in the urine of females could be used to confirm pregnancy. In the 1920s it was injecting urine into female rabbits that after a day would require the examination of the rabbit ovaries. If swollen the woman was pregnant. In order to do the examination the rabbit was always killed and so the search continued for a better option.

Enter Lancelot Hogben, an English researcher lecturing in Cape Town in the early 1930s. He advised a student to consider using the local platanna as a potential for use as a model organism for biological tests. His hunch proved correct with Hillel Shapiro and Harry Zwarenstein creating the test to use the frog to indicate pregnancy.

The frog would be injected and in hours if the woman was pregnant would produce eggs. Not only was it accurate, but it also would not harm the frog which was easy to keep in a lab and would live for over a decade. As a result, the remarkable frog was exported around the globe and provided the answer to the question, am I pregnant, to the largest population explosion in our history. Most baby boomers parents and indeed many baby boomers would have found out if they were pregnant thanks to this strange-footed frog.

Xenopus literally means strange foot, frogs typically dont have claws which is why the African clawed frog got the name and as for Platanna, that may be a reference to the frog being very flat - plat in Afrikaans.

Given its widespread use for pregnancy and acceptance as a good species for embryonic development when researchers attempted to clone an organism, this frog was once again a key in understanding the process. In 1958, Xenopus was cloned not from splitting an embryonic cell which was the original method, but by using the DNA from an adult specialised cell which replaced the original DNA in a frog egg. The method proved successful and paved the way to allow Dolly the sheep to be cloned from an adult sheep cell in 1996.

We owe a huge debt of gratitude to six species that for a variety of reasons have helped us understand biological processes and how best to deal with disease and the efficacy of drugs. There are nematode worms, fruit flies, zebrafish, chickens, mice and the African clawed toad.

These six animals are our real guinea pigs.

Image credit: Xenobot - Tuft University & University of Vermont

View post:
Biological robots, that is a thing now - 702

Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes – International Business Times

KEY POINTS

Type 2 diabetes has affected more than 30 million Americans till date.The condition usually occurs in individuals above the age of 45. But children, teens, and young adults are also developing it these days. Researchers have been finding ways to prevent and reverse the condition.

Researchers at Yale University have come up with a new way to reverse type 2 diabetes. They have identified a couple of proteins that could prevent diabetes when knocked down. According to the study, fasting switches on a certain process in the body in which the proteins TET3 and HNF4a increase in the liver and produces blood glucose. In type 2 diabetes patients, this switch fails to turn off after fasting.

Thus, they hypothesized that knocking down these two proteins could stop diabetes from developing.

In the Study published in cell reports, the researchers injected mice with genetic material called small interfering RNAs packaged inside viruses that target these two proteins. They found that insulin and blood glucose levels dropped significantly.

They also discovered that TET3 contributed to the development of liver fibrosis. They discovered that the protein TET3 plays a vital role in the fibrosis signaling pathway in three different locations acting as an important regulator in the development of liver fibrosis.

The findings of the study pave the way for opportunities in developing drugs that inhibit TET3 to slow or reverse fibrosis. Although liver fibrosis and type 2 diabetes are common conditions, there are very few treatment options currently.

Diabetes can lead to several other health conditions including stroke, kidney diseases, and heart diseases. Whereasliver fibrosis can lead to cirrhosis, which is one of the leading causes of death worldwide, according to the experts at Yale Liver Center.

Although there are drugs including metformin to control blood sugar levels in diabetic patients, they are subjected to a wide range of unpleasant side effects and moreover, patients consuming them can develop resistance to them.

While much is known about the role of TETs in development, stem cells, and cancer, little is known about their role in energy metabolism. In the current study we report an unexpected finding of P2 promoter reactivation in the adult liver by TET3 with an essential role in the control of hepatic glucose production (HGP), said the researchers.

diabetes symptoms shin spots Photo: stevepb - Pixabay

Follow this link:
Knocking Down Levels Of These Proteins Could Reverse Type 2 Diabetes - International Business Times

Immune therapy tweak offers new hope to blood cancer patients – NBC News

A retired Texan had endured 12 years of chemotherapy for blood cancer only to see the disease come back stronger and meaner each time.

It was long, hard and terrible, J.C. Cox, 66, said.

So when he was told that he could take part in a clinical trial of a newly modified form of immune therapy, he signed on.

In that small preliminary trial, the results of which were published Wednesday in the New England Journal of Medicine, nearly two-thirds of the patients, all of whom had cancer so advanced that just a decade ago there would have been no hope for them, went into complete remission. Cox was among that two-thirds.

The new treatment involves tweaking a type of therapy called CAR-T that helps the immune system home in on cancer cells. Those tweaks appear to have made it more effective than its predecessor while also leading to fewer side effects, the study found.

In CAR-T therapy, doctors equip a patients own T-cells with a sensor that essentially sniffs out a protein on cancer cells, allowing them to glom onto the protein and then destroy the diseased cells. CAR-T therapy has been approved by the U.S. Food and Drug Administration to treat several types of blood cancer.

The altered T cells end up working like a heat-seeking missile, said study co-author Dr. Katayoun Rezvani, a professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center.

There were several drawbacks to CAR-T, including the time it took to make the revved up T cells which needed to be harvested from patients and then sent to a lab, their cost, and most important, the possibility of life-threatening side effects.

To try to make a cheaper, safer therapy that would potentially work for all patients, Rezvani and her colleagues switched from T-cells to a different type of immune cell, called natural killer cells.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Natural killer cells are the best killers of virally infected and abnormal cells, she said. They can continue to patrol and recognize abnormal cells.

There were several advantages to the natural killer cells, not the least of which was that, unlike T cells, they wouldnt make the patients sick by spewing out a flood of inflammatory proteins, leading to a severe condition called a cytokine storm. Another big advantage was that the natural killer cells from one patient could be given to another without any tissue matching. That meant that such cells from healthy donors or from donated umbilical cord blood could be banked and ready to use at any time.

Presumably, this would cut down on the wait time and the costs of the therapy, because the treatments werent being tailor-made for each individual patient.

Rezvani and her colleagues genetically modified the natural killer cells to have a receptor (the R in CAR) for a protein that is on the surface of the cancer cells they were targeting. The receptor would lock onto the protein and then the cell would do its work.

The researchers also tweaked the natural killer cells in two other ways. Unlike T cells which live for a long time, natural killer cells normally have a lifespan of just a couple of weeks, so the researchers added a growth factor that would keep them around for a lot longer. And as a precaution, they also inserted a switch that would allow the researchers to kill off the altered cells if they became too abundant.

Rezvani and her colleagues tested the new treatment in 11 blood cancer patients. When the patients were checked two months after treatment, seven had no signs of cancer while one other showed improvement but not complete remission. The other three had no response to the treatment.

Cox was the eighth patient to receive the new treatment, and initially had misgivings.

I didnt have any other options, Cox, who received the treatment for non-Hodgkin lymphoma, said. But it was scary knowing I would be No. 8 and would be getting the biggest dose.

The trial had been set up to start with a low dose, and then wait to see if there were any serious side effects. If not, the plan was to increase the dose in later patients.

Coxs years of chemotherapy made him worry about possible side effects. But it was probably the easiest thing Ive ever done, he said.

The researchers themselves werent sure what to expect. We were amazed at the safety, Rezvani said. And it didnt seem to matter what dose we gave. This truly is a living drug. It gets inside of the patients body and starts growing and attacking the cancer cells.

Larger studies are needed, but if the treatment which has been licensed to Takeda Pharmaceutical Co. lives up to its early promise, Rezvani hopes to try it on other cancers, such as ones that affect the brain and the breasts.

The response of the patients in the new study is impressive, said Dr. David Porter, the director of cell therapy and transplantation at the University of Pennsylvania Health System. I think this is a major advance in the field of targeted cellular therapy.

Moreover, the natural killer treatments dont seem to have the same life-threatening complications as the original CAR-T therapy, Porter said in an email. Porter was involved with previous CAR-T research, but was not involved with this trial.

But, Porter cautioned, the study included a very small number of patients.

Cox wasnt sure what to expect when he went to be checked two months after receiving his treatment. The news was better than he could have imagined: there was no sign of his cancer.

I did a lot of crying, but they were happy tears, he said. I still get emotional when I talk about it.

Follow NBC HEALTH on Twitter & Facebook.

The rest is here:
Immune therapy tweak offers new hope to blood cancer patients - NBC News

First CAR-T cell cancer therapy patient in Delaware – Dover Post

'This is the beginning of my new life'

I thought my cancer diagnosis was a death sentence, said Lynnette Williams-Briggs, 60, of Seaford, Delaware, who was diagnosed with advanced B-cell lymphoma in 2018.

Briggs cancer is now in complete remission thanks to successful chimeric antigen receptor CAR-T cell therapy she received in August atChristianaCaresHelen F. Graham Cancer Center & Research InstitutesBone Marrow and Stem Cell Transplant Program.

I can breathe again. This is the beginning of my new life, Williams-Briggs said following the treatment that restored her hope for a second chance at life.

She was the first patient to receive CAR-T cell therapy in Delaware. A second patient was treated in December 2019, and doctors are preparing several more patients for CAR-T cell transplants in coming weeks.

The U.S. Food and Drug Administration has approved CAR-T cell therapy to treat patients like Williams-Briggs with highly resistant, B-cell blood cancers, for whom other available options have failed.

CAR-T cell therapy is only available at select cancer centers with specialized expertise in cellular therapies that are recognized for quality by the Foundation for the Accreditation of Cellular Therapy.

The Graham Cancer Centers Bone Marrow and Stem Cell Transplant Program is the only one in Delaware that is certified to treat adult patients with advanced B-cell lymphomas and children and young adults (to age 25) with acute lymphoblastic leukemia, using an FDA-approved drug.

CAR-T cell therapy is highly personalized medicine that attempts to use the bodys natural defenses to fight against cancer. The transplant team extracts millions of T cells, from the patients bloodstream, using a specialized blood filtration process called leukapheresis. The collected T cells are flash-frozen and sent to a lab for reprogramming, and then later infused back into the patient using a process similar to a blood transfusion.

The therapy is considered a living drug with potential benefits that could last for years.

When we first met Ms. Williams-Briggs, her cancer had progressed rapidly despite a third round of chemotherapy, so we knew we had to move quickly, said Graham Cancer Center Hematologist Peter Abdelmessieh, D.O. He worked closely with the bone marrow/stem cell transplant team and Graham Cancer Center leadership over the course of just eight months to develop the CAR-T cell therapy program.

It was truly a team effort to bring CAR-T cell therapy to our community so quickly, Dr. Abdelmessieh said.

CAR-T cell therapy has been extremely effective for many patients like Williams-Briggs, whose PET scan at 90 days confirmed her remission.

The supercharged T cells Williams-Briggs received were genetically modified in the lab to sprout new surface tools that improve their ability to recognize, latch onto and destroy other cells (including cancer cells) that express a specific antigen called CD19. These reprogrammed cells continue to multiply in the body after treatment, remaining on guard to seek and destroy any new cancers that might develop.

With continued success in increasing numbers of patients, it is conceivable that in the not too distant future, CAR-T cell therapy could become the new standard of care, replacing chemotherapy and stem cell transplants for many cancers, Dr. Abdelmessieh said.

The extended recovery period for CAR-T cell therapy is generally two to three months. After the infusion, patients may spend up to three weeks in the hospital to monitor treatment response and any side effects.

During the first 30 days after leaving the hospital, patients are required to remain close to the treatment center for regular follow-up care.

The ability to offer potentially life-saving CAR-T cell therapy is one more reason our patients need not travel further than the Graham Cancer Center for state-of-the-science cancer treatment, said Nicholas J. Petrelli, M.D., Bank of America medical director of the Helen F. Graham Cancer Center & Research Institute.

The Bone Marrow and Stem Cell Transplant Program is an outstanding example of how well our clinical teams work together to drive innovation in patient care.

Although patients normally do not experience the side effects associated with chemotherapy, such as nausea, vomiting or hair loss, CAR-T cell therapy is not without risks. A common side effect, which Williams-Briggs also experienced, is cytokine release syndrome. This is an inflammatory condition that causes flu-like symptoms that may be mild or severe.

The transplant team responded quickly to manage her symptoms while she received expert care on the Bone Marrow Transplant and Oncology unit at Christiana Hospital.

From the moment I first met with my transplant team, I felt like I was part of one big loving family that extended beyond my own loved ones, Williams-Briggs said.

Dr. Abdelmessieh and my ChristianaCare family gave me hope to keep fighting when I really didnt think I would make it. I would have driven anywhere to get life-saving treatment, but I am thankful that I did not have to. I found my miracle closer to home.

Excerpt from:
First CAR-T cell cancer therapy patient in Delaware - Dover Post

Stem Cell Therapy Market Trends and Growth, Outlook, Research, Trends and Forecast to 2025 – Instant Tech News

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

View post:
Stem Cell Therapy Market Trends and Growth, Outlook, Research, Trends and Forecast to 2025 - Instant Tech News

4-year-old thalassemia surivor meets lifesaver for first time – Devdiscourse

This World Cancer Day, Bengaluru witnessed a heart-warming moment where a thalassemia survivor met her lifesaver for the first time. A techie from the city had donated his blood stem cells giving a second chance at life to the four-year-old Shia from West Bengal suffering from thalassemia.

The meeting was organized by the non-profit organization DKMS BMST Foundation India, an international blood stem cell donor registry. Shia flew for the first time and came here to meet her lifesaver Debojyoti, a 26-year-old techie, who donated his blood stem cells so that she could receive a second chance at life.

Expressing his emotions on World Cancer Day on Tuesday, Debojyoti told reporters he had registered himself as a potential stem cell donor in 2016 and after a year of registration he was found to be a match. "I did not know the details of the patient to whom my blood stem cells will be given but now when I met her after all these years, I went numb. Being able to save a life is a feeling beyond words. It can only be experienced-cant be described," he said.

When this family residing in Kolkata found their daughter suffering from thalassemia, they researched the treatments available. Sharing their experience, Shias father Saifulla said due to lack of awareness about the blood stem cell transplant procedure they were turned down by the local doctors.

"We were told that our daughter will need blood transfusion throughout her life to survive, we were devastated but kept doing our research. We got a ray of hope after meeting Dr. Revathi Raj based in Chennai and she assured us of treatment available in the form of a blood stem cell transplant, he said. That when the journey to find an unrelated blood stem cell match began for the family.

With the help of doctors, they were lucky to find a match for their daughter within a year and she underwent a blood stem cell transplantation. Director of DKMS-BMST Dr. Latha Jagannathan said many patients suffering from blood cancer and other blood disorders need a blood stem cell transplant to survive.

"Unfortunately, the majority of patients are unable to receive a transplant due to the unavailability of a matching blood stem cell donor", she said. The registry DKMS-BMST at present has over 40,000 registered potential blood stem cell donors.

"We will work hard that this number will increase considerably over the coming years", she added. Pediatric hematologist, oncologist, and BMT specialist at Narayana Health City, Bengaluru, Dr. Pooja Prakash Mallya said every five minutes someone in India is diagnosed with blood cancer and other blood disorders. And many are not able to find a match within their families and hence need an unrelated donor.

This gap can be bridged only when more and more people from different ethnicities in India are a part of the donor registry maintained by organizations such as DKMS-BMST, she said. CEO of DKMS BMST Foundation India Patrick Paul said mostly, for blood cancer patients a blood stem cell transplant is key for survival.

"Each one of us should register as a potential stem cell donor and encourage our near and dear ones to register themselves too", he said. As per protocols, the identity of both the donor and recipient is kept anonymous for a period of two years and thereafter upon interest, they can be introduced to each other.

Ever since I donated my blood stem cells, I was looking forward to meeting the recipient. I only knew her age and today I am glad that I could see her and meet her family, Debojyoti said. Today, Shia is leading a normal life and is a hale and hearty girl who likes to draw and color and is probably not even completely aware of the condition she was in, a DKMS-BMST statement said.

All she knows is Debojyoti is a friend who gifted her something she would cherish forever. DKMS-BMST is a joint venture of two non-profit organizations: BMST (Bangalore Medical Services Trust) and DKMS, one of the largest international blood stem cell donor registries in the world.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Download The Devdiscourse News App for Latest News.

The rest is here:
4-year-old thalassemia surivor meets lifesaver for first time - Devdiscourse